SG Americas Securities’s Tourmaline Bio TRML Stock Holding History

SG Americas Securities’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,182	Closed	-$965K	–	3771
2025 Q3	$965K	Sell	20,182 -44,974	-69%	-$1.25M	﹤0.01%	1502
2025 Q2	$1.04M	Buy	65,156 +28,976	+80%	+$469K	﹤0.01%	1159
2025 Q1	$550K	Buy	36,180 +1,368	+4%	+$21.9K	﹤0.01%	1697
2024 Q4	$706K	Buy	34,812 +1,140	+3%	+$28.7K	﹤0.01%	1065
2024 Q3	$866K	Buy	33,672 +6	+0%	+$100	﹤0.01%	1198
2024 Q2	$433K	Buy	+33,666	New	+$542K	﹤0.01%	1747
2022 Q4	–	Sell	-1,040	Closed	-$27K	–	3382
2022 Q3	$27K	Buy	+1,040	New	+$37.9K	﹤0.01%	3076

SG Americas Securities's TRML Position: Q4 2025 in Review

SG Americas Securities sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 20,182 shares — an estimated $965K sold.

SG Americas Securities first reported a position in TRML in Q3 2022 and held it in 7 quarters. The position peaked at $1.04M in Q2 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

SG Americas Securities reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
SG Americas Securities sold 20,182 Tourmaline Bio shares in Q4 2025, an estimated $965K.
SG Americas Securities first reported a position in Tourmaline Bio in Q3 2022 and held it in 7 quarters.
SG Americas Securities's Tourmaline Bio position peaked at $1.04M in Q2 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on SG Americas Securities's 13F filing for Q4 2025, filed 9 Jan 2026.